Medical Device Software (MDSW) is becoming essential in EU healthcare, especially as hospitals and patients rely more on digital tools for diagnosis, monitoring, and clinical decision-making. Under the EU Medical Device Regulation (MDR 2017/745) and In Vitro Diagnostic Regulation (IVDR 2017/746), any software used for medical purposes such as analyzing health data, helping doctors make decisions, or supporting IVD tests is legally considered a medical device and must meet strict safety and performance requirements.

The EU classifies medical software based on the risk it poses to patients. Under MDR, software that supports high-risk decisions (for example, decisions that may lead to serious harm if wrong) falls under higher classes like Class IIb or III. Under IVDR, software used with diagnostic tests is classified from Class A to D depending on how critical the test is. Whether the software is a mobile app or built inside a device, it must follow the same rules: clear intended purpose, proper validation, cybersecurity protection, and safe usability.

To be sold in Europe, MDSW must undergo conformity assessment and receive CE marking. This involves preparing technical documentation that explains how the software was developed, tested, and secured. Manufacturers must also show clinical or performance evidence proving that the software works safely and as intended. After approval, companies must monitor how the software performs in the real world, report issues, and update it responsibly without introducing new risks.

As Europe moves toward digital health systems like telemedicine, AI-based tools, and cross-border health data sharing, MDSW plays a major role. The regulations may seem strict, but they ensure safer, more reliable digital healthcare. Morulaa can support companies through the entire process classification, documentation, CE marking, Notified Body interactions, and post-market surveillance making compliance easier for manufacturers entering or expanding in the EU market.